Form 4: Ultragenyx SVP Theodore Alan Huizenga Reports Stock Transactions

Ultragenyx Pharmaceutical's SVP, Chief Accounting Officer Theodore Alan Huizenga, reports acquisition and disposal of company stock and stock options.

Summary

• On March 1, 2025, Theodore Alan Huizenga, SVP, Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., was awarded 9,392 shares of common stock as Restricted Stock Units (RSUs) under the company's 2023 Incentive Plan.
• These RSUs vest in equal installments over four years from the grant date.
• On March 3, 2025, Huizenga sold 967 shares of common stock at an average price of $42.1 per share.
• Also on March 3, 2025, 141 shares were surrendered to the issuer to cover tax withholdings related to the vesting of RSUs, valued at $42.92 per share.
• Huizenga also acquired 5,632 stock options with an exercise price of $42.92 on March 1, 2025, vesting over four years with a ten-year expiration.
• Following these transactions, Huizenga beneficially owns 50,124 shares of common stock and 5,632 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects routine transactions related to executive compensation. The sale of shares is likely for tax purposes and doesn't necessarily indicate a negative outlook.

Positives

• The grant of RSUs and stock options to a key executive suggests the company's commitment to aligning management's interests with those of shareholders.

Negatives

• The sale of shares by Huizenga, even if for tax purposes, could be interpreted negatively by some investors, although it's a common practice after RSU vesting.

Risks

• Executive stock sales can sometimes be perceived as a lack of confidence in the company's future performance, although this sale appears to be related to tax obligations.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry, used by companies like Amgen, Biogen, and Vertex to incentivize performance and retain key personnel.
• The vesting schedules and terms of these grants are generally in line with industry standards, with vesting typically occurring over a period of 3-4 years.

Stakeholder Impact

• The transactions have a minor impact on shareholders, providing transparency into executive compensation and stock ownership.
• Employees may be indirectly affected by the perceived alignment of management's interests with the company's performance.

Key Dates